Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Advanced Solid Tumors
Interventions: JAB-23E73, Cetuximab; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more

Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions: CD7.CAR/28zeta T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2043
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer
Interventions: Palliative Radiation and Pembrolizumab; Combination Product
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Neoplasms, Advanced Solid Tumors
Interventions: JNJ-87890387; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Nashville, Tennessee

Conditions: Alcohol Use Disorder (AUD)
Interventions: Alcohol Cue Reactivity Paradigm; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions: Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil); Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 69
States / cities: Chandler, Arizona • Phoenix, Arizona • Coronado, California + 51 more

Conditions: Knee Injuries, Shoulder Injuries, Pain, Postoperative
Interventions: Endonovo SofPulse; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Post Stroke Depression
Interventions: Zuranolone; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Oral Mucositis, Periodontal Diseases, Cancer
Interventions: Telehealth Intervention (THI); Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Autism Spectrum Disorder, PTSD and Trauma-related Symptoms, Autism, Trauma and Stressor Related Disorders, Mental Health Services
Interventions: Trauma-Focused Cognitive Behavioral Therapy, modified for autistic youth; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 6 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Anxiety, Radiation
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Interventions: Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Urea Cycle Disorder, Organic Acidemia, Maple Syrup Urine Disease, Glutaric Acidemia I, Fatty Acid Oxidation Disorder, Hypoxic-Ischemic Encephalopathy
Interventions: Not listed
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, Access and Linkage to Healthcare, Technology Use
Interventions: PEPPI Pharmacies; Other
Lead sponsor: EMPOWERX INC; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Digestive Health, Quality of Life
Interventions: Fermented dairy protein with prebiotic fiber supplement, Control placebo; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Difficult Vein Access, Emergency Department Patients, Nurses Role, Midline Catheter, Ultrasound Assistance, Difficult Intravenous Access, Catheterization, Peripheral, Catheterization, Emergency Service, Hospital
Interventions: Ultrasound-Guided Single-Lumen Midline Catheter, Ultrasound-Guided Long Peripheral Intravenous Catheter; Device
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Albany, New York

Conditions: Breast Cancer
Interventions: Aromatase inhibitors or tamoxifen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Functional Seizures, Convulsion, Non-Epileptic
Interventions: ReACT, CATCH-IT; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 11 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Cancer
Interventions: Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab, REGN7075; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer, Caregiver Burden, Health Knowledge, Attitudes, Practice
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions: KindVR Aqua Program; Device
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Covid19
Interventions: Defibrotide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: Venetoclax; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: West Hollywood, California • Omaha, Nebraska

Search by objective public record fields.

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

A Study of JNJ-87890387 for Advanced Solid Tumors

Sensory and Physical Reactions to Beverage Cues

Allo HSCT for High Risk Hemoglobinopathies

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery

Allopregnanolone (Zuranolone) in Post-stroke Depression

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

TF-CBT for Autistic Youth Pilot Implementation - Open Pilot

Baseline Anxiety Trajectories in Pediatric Radiation Therapy Observational Cohort

Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS

Systemic Biomarkers of Brain Injury From Hyperammonemia

PEP/PrEP Via Pharmacist-Prescribing Implementation (PEPPI)

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

Single Lumen Midline Catheter vs Ultrasound Guided Peripheral IV as Performed by Bedside Emergency Department Registered Nurses

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

NLit and Outcomes in HNC Survivor-Caregiver Dyads

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

Defibrotide for the Treatment of Severe COVID-19

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma